Bellicum Pharmaceuticals (NASDAQ: BLCM) is one of 288 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its competitors? We will compare Bellicum Pharmaceuticals to related companies based on the strength of its profitability, risk, dividends, valuation, earnings, analyst recommendations and institutional ownership.

Volatility & Risk

Bellicum Pharmaceuticals has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500. Comparatively, Bellicum Pharmaceuticals’ competitors have a beta of 6.57, meaning that their average stock price is 557% more volatile than the S&P 500.

Earnings and Valuation

This table compares Bellicum Pharmaceuticals and its competitors gross revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Bellicum Pharmaceuticals $323,000.00 -$79.18 million -3.99
Bellicum Pharmaceuticals Competitors $464.68 million $167.54 million -6.57

Bellicum Pharmaceuticals’ competitors have higher revenue and earnings than Bellicum Pharmaceuticals. Bellicum Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a summary of recent ratings and price targets for Bellicum Pharmaceuticals and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bellicum Pharmaceuticals 0 0 5 0 3.00
Bellicum Pharmaceuticals Competitors 1377 4466 12278 311 2.63

Bellicum Pharmaceuticals presently has a consensus target price of $26.20, suggesting a potential upside of 123.55%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 34.24%. Given Bellicum Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Bellicum Pharmaceuticals is more favorable than its competitors.

Profitability

This table compares Bellicum Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Bellicum Pharmaceuticals -17,957.31% -70.74% -53.29%
Bellicum Pharmaceuticals Competitors -4,766.74% -354.83% -43.39%

Institutional and Insider Ownership

55.7% of Bellicum Pharmaceuticals shares are owned by institutional investors. Comparatively, 51.6% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 23.3% of Bellicum Pharmaceuticals shares are owned by company insiders. Comparatively, 17.4% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

About Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system. The Company is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy and T-cell receptor (TCR) cell therapies. The Company’s product candidates include BPX-501, BPX-601 and BPX-701. The Company’s CID-based technologies include CaspaCIDe and GoCAR-T. It is evaluating BPX-501 in various Phase I/II clinical trials in adults and pediatric patients with leukemias, lymphomas and genetic blood diseases in the United States and Europe.

Receive News & Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.